Results 121 to 130 of about 3,775,993 (302)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

Journal of Market Access & Health Policy, 2017
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct ...
Z. Kaló, Z. Vokó, A. Östör, E. Clifton-Brown, R. Vasilescu, A. Battersby, E. Gibson   +6 more
semanticscholar   +1 more source

Editorial: Antirheumatic drugs: plenty is not enough. [PDF]

, 1976

openalex   +1 more source

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis

Patient Preference and Adherence, 2016
Objective Nonadherence in rheumatoid arthritis (RA) patients using disease-modifying antirheumatic drugs (DMARDs) may lead to joint damage and function loss.
Yunfei Xia, R. Yin, T. Fu, Lijuan Zhang, Qiuxiang Zhang, G. Guo, Liren Li, Z. Gu   +7 more
semanticscholar   +1 more source

The Role of Analgesic Antirheumatic Drugs in Precipitating Acute Upper Gastrointestinal Bleeding [PDF]

, 1977
M J Langman
openalex   +1 more source

REVIEW OF THE 2017 AMERICAN COLLEGE OF RHEUMATOLOGY/AMERICAN ASSOCIATION OF HIP AND KNEE SURGEONS GUIDELINES FOR THE PERIOPERATIVE MANAGEMENT AND ANTIRHEUMATIC THERAPY OF PATIENTS WITH RHEUMATIC DISEASES BEFORE TOTAL KNEE AND HIP ARTHROPLASTY

Научно-практическая ревматология, 2018
The article presents the guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons for the perioperative management of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirdzhanova, A. E. Karateev, E. Yu. Pogozheva   +2 more
doaj   +1 more source

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. [PDF]

, 2019
Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX ...
DeHoratius, Raphael J., Ellis, Lorie A., Kafka, Shelly, Kubacki, Maureen, Malangone-Monaco, Elisabetta, Stetsovsky, Diana, Varker, Helen   +6 more
core   +1 more source

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis [PDF]

, 2013
BACKGROUND: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US Food and Drug Administration (FDA). There are several randomised clinical trials (RCTs) that have investigated the efficacy and safety of ...
Chan, EWY, Chui, CSL, He, Y, Lau, WCY, Man, KC, Wong, AYS, Wong, ICK, Worsley, AJ   +7 more
core   +3 more sources

Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis: in vivo inhibition by the antirheumatic drug piroxicam due to interference with the activation of the NADPH-oxidase. [PDF]

, 1986
P Biemond, A. J. G. Swaak, J.M.A Penders, C M Beindorff, J.F. Koster   +4 more
openalex   +1 more source

Disease Modifying Anti-Rheumatic Drugs: Review on Pregnancy and Lactation

Journal of Clinical Rheumatology and Immunology, 2019
Rheumatic diseases occur commonly in patients of childbearing age. The compatibility of different Disease Modifying Anti-Rheumatic Drugs (DMARDs) during pregnancy and lactation can affect the management decision when treating these patients.
Tsz-Yuen wu, King-Yee Ying
doaj   +1 more source

Effects of Analgesic and Antirheumatic Drugs on the Assay of Serum Enzymes [PDF]

, 1984
Z. Jelić, Nada Majkić‐Singh, Snežana Spasić, P Todorović, D. Živanov‐Stakić   +4 more
openalex   +1 more source